Literature DB >> 16206199

Impact of a national beta-thalassemia carrier screening program on the birth rate of thalassemia major.

Jimmy P S Chern1, Kai-Hsin Lin, Yi-Ning Su, Meng-Yao Lu, Shiann-Tarng Jou, Dong-Tsamn Lin, Shih-Chung Wang, Kuo-Sin Lin.   

Abstract

BACKGROUND: In Taiwan, the prevalence of beta-thalassemia trait is at least 1.1%. The Taiwan government initiated a National Screening Program in 1993. Herein we examine the differences before and after the initiation of this program. PROCEDURE: Data consisting of the total number of patients and the birth prevalence beta-thalassemia major were collected. Ninety-one patients with transfusion-dependent thalassemia treated in our hospitals were included for analysis. DNA analysis was performed for 86 patients.
RESULTS: In Taiwan 361 patients exist. The birth prevalence of per 100,000 births was 5.6% in 1994 and declined to 1.21 in 2002. Fourteen patients were born after the program's initiation. DNA analysis of them revealed a new mutation (IVS-1-5 (G-C)), which was introduced through an inter-racial marriage. Otherwise, the remainder was the common beta-thalassemia mutations found in Taiwan.
CONCLUSIONS: Despite how successful the National Screening Program is, a few doctors still failed to detect parents at risk. In addition, we are concerned about the emerging problem of the increase of interracial marriages where parents may not have appropriate screening. Hence, postgraduate education programs for physicians, health education for the general population, and timely screening of inter-racial marriage should become a priority.

Entities:  

Mesh:

Year:  2006        PMID: 16206199     DOI: 10.1002/pbc.20343

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

Review 1.  Carrier screening for beta-thalassaemia: a review of international practice.

Authors:  Nicole E Cousens; Clara L Gaff; Sylvia A Metcalfe; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

2.  The future of neo-eugenics. Now that many people approve the elimination of certain genetically defective fetuses, is society closer to screening all fetuses for all known mutations?

Authors:  Armand Marie Leroi
Journal:  EMBO Rep       Date:  2006-12       Impact factor: 8.807

3.  Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis.

Authors:  Chao-Hsiun Tang; Wesley Furnback; Bruce C M Wang; Jackson Tang; Derek Tang; Meng-Yao Lu; Vicky W-H Huang; Khaled M Musallam
Journal:  Transfusion       Date:  2021-09-10       Impact factor: 3.337

Review 4.  The prevention of thalassemia.

Authors:  Antonio Cao; Yuet Wai Kan
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

Review 5.  Iron chelation therapy in the management of thalassemia: the Asian perspectives.

Authors:  Vip Viprakasit; Chan Lee-Lee; Quah Thuan Chong; Kai-Hsin Lin; Archrob Khuhapinant
Journal:  Int J Hematol       Date:  2009-10-29       Impact factor: 2.490

6.  Discrimination index of microcytic anemia in young soldiers: a single institutional analysis.

Authors:  Tzu-Chuan Huang; Yi-Ying Wu; Yu-Guang Chen; Shiue-Wei Lai; Sheng-Cheng Wu; Ren-Hua Ye; Chieh-Sheng Lu; Jia-Hong Chen
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

7.  The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.

Authors:  Hsiu-Hao Chang; Meng-Yao Lu; Steven Shinn-Forng Peng; Yung-Li Yang; Dong-Tsamn Lin; Shiann-Tarng Jou; Kai-Hsin Lin
Journal:  Ann Hematol       Date:  2015-09-25       Impact factor: 3.673

8.  Pediatric thalassemic patients have higher incidence of asthma: A nationwide population-based retrospective cohort study.

Authors:  Hsin-Yi Hsieh; Lin-Chi Huang; Hong-Ren Yu; Kuang-Che Kuo; Wan-Hsuan Chen; Chung-Hao Su; Chuan-Pin Lee; Ko-Jung Chen; Yao-Hsu Yang; Jiunn-Ming Sheen
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.